A study examining sPD-L1 levels in 39 NSCLC patients also found that most patients with high levels (75% of patients) did not respond to Nivolumab, while a high proportion of patients (59%) with low sPD-L1 showed durable response to Nivolumab [138]. Here, SPDL1 is linked to non-small cell lung carcinoma.